Garwood Medical Devices manufactures implantable medical devices designed to control bacterial biofilm infections, which affect 2.2% of knee and hip implants annually. Their BioPrax™ technology aims to enhance patient outcomes by enabling implant retention through early intervention, addressing the high failure rates of current treatment methods.
Funding
Funding not disclosed
Founders
Product
Problem
Bacterial biofilm infections following knee and hip implant surgeries affect a significant percentage of patients annually, leading to high treatment failure rates and, in some cases, increased mortality. Current treatment methods often fail to eradicate the infection, necessitating implant removal and revision surgery.
Solution
Garwood Medical Devices is developing BioPrax™, an implantable medical device designed to control bacterial biofilm infections associated with orthopedic implants. The BioPrax™ technology aims to enhance patient outcomes by enabling implant retention through early intervention, addressing the limitations of current treatments. This innovative approach focuses on eradicating the infection early, potentially avoiding implant removal and revision surgeries, and improving the overall standard of care for patients with implant-related infections. The technology is currently under investigation for FDA marketing authorization.
Target Audience
The primary target audience includes patients undergoing knee and hip implant surgeries who are at risk of developing bacterial biofilm infections, as well as orthopedic surgeons and hospitals seeking innovative solutions for managing these infections.
Features
- Implantable device designed for early intervention in bacterial biofilm infections.
- Aims to enhance implant retention rates.
- Focuses on improving patient outcomes by addressing the limitations of current treatment methods.